* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a rise in quarterly revenue when it reports
results
* The Princeton New Jersey-based company is expected to
report a
0.5% increase in revenue to $387.125 million from $385.19
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. The company's guidance on
July 26 2023, for the period ended September 30, was for revenue
between $386.00 million and $390.00 million.
* Refinitiv's mean analyst estimate for Integra
Lifesciences
Holdings Corp is for earnings of 78 cents per share. The
company's EPS guidance on July 26 2023, for the period ended
September 30, was between $0.76 and $0.80
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 6
"hold" and 5 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $46, above its last closing
price of $37.94.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.57 0.57 0.71 Beat 24.8
Mar. 31 2023 0.74 0.74 0.74 Met 0.4
Dec. 31 2022 0.91 0.90 0.94 Beat 4.1
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jun. 0.80 0.80 0.81 Beat 1.6
30 2022
Mar. 31 2022 0.68 0.68 0.74 Beat 8.8
Dec. 31 2021 0.84 0.83 0.84 Beat 0.7
Sep. 30 2021 0.72 0.72 0.86 Beat 18.7
This summary was machine generated October 23 at 16:43 GMT. All
figures in US dollars unless otherwise stated